Robert J. Kreitman - Concepedia

Author

Robert J. Kreitman

Also Known As

R J Kreitman, R Kreitman, R. J. Kreitman, R. Kreitman, R.J. Kreitman, Robert J Kreitman, Robert J. Kreitman, Robert J. Kreitman,, Robert J. Kreitman, MD, Robert Kreitman

346

Publications

17K

Citations

H-Index

124

Concepts

All Affiliations

National Cancer Institute National Institutes of Health Center for Cancer Research The University of Texas MD Anderson Cancer Center Wake Forest University

About

Robert J. Kreitman is an author at National Cancer Institute specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	75	5.4K
2	Health Sciences	9	9	459
3	Natural Sciences	8	8	509
4	Engineering	2	2	68
5	Social Sciences	1	1	228

Robert J. Kreitman

164

Publications

13.7K

Citations

H-Index

Page 1

	Year	Citations
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Journal of Clinical Oncology Trametinib TreatmentConclusion DabrafenibMedicineRadionuclide TherapyLocally Advanced	2017	848
Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia Robert J. Kreitman, Wyndham H. Wilson, Karen Bergeron, New England Journal of Medicine	2001	508
Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies Robert J. Kreitman, Wyndham H. Wilson, Jeffrey D. White, Journal of Clinical Oncology	2000	420
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers Raffit Hassan, Susie Bullock, Ahalya Premkumar, Clinical Cancer Research	2007	379
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Annals of Oncology	2022	319
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia Robert J. Kreitman, Martin S. Tallman, Tadeusz Robak, Journal of Clinical Oncology	2012	296
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos, Blood	2016	271
High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemias Joshua J. Waterfall, Evgeny Arons, Robert L. Walker, Nature Genetics Hematological MalignancyIghv4-34–expressing Hairy-cell LeukemiasMedicineGeneticsPathology	2013	270
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies Robert J. Kreitman, David Squires, Maryalice Stetler‐Stevenson, Journal of Clinical Oncology	2005	256
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Nature Medicine	2023	252

Page 1